Glaxosmithkline Pharmaceuticals Ltd (GLAXO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 793005,
    "name": "Glaxosmi. Pharma",
    "stock_name": "Glaxosmi. Pharma",
    "full_name": "Glaxosmithkline Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/glaxosmi-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,266.85",
    "chg": 68,
    "chgp": "3.09%",
    "dir": 1,
    "prev_price": "2,198.85",
    "mcapval": "38,401.81 Cr",
    "mcap": "Mid Cap",
    "scripcode": 500660,
    "symbol": "GLAXO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE159A01016",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "2.83 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3987324",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Glaxosmithkline_mojoScore_3987324.png",
        "date": "2026-05-12 10:10:46",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3953815",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_mojoScore_3953815.png",
        "date": "2026-04-20 10:10:48",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3939384",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_mojoScore_3939384.png",
        "date": "2026-04-09 10:10:32",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-bearish-momentum-amid-technical-downgrade-3933755",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_technicaldot_3933755.png",
        "date": "2026-04-06 08:01:52",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO, accompanied by a Mojo Score of 43.0, reflects growing concerns over its near-term price performance amid a challenging market environment."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-bearish-momentum-amid-technical-downgrade-3923410",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_technicaldot_3923410.png",
        "date": "2026-03-30 08:02:06",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum, underscoring challenges ahead for investors in this mid-cap pharmaceutical stock."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3921542",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_mojoScore_3921542.png",
        "date": "2026-03-28 10:10:03",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 15,
    "sid": "793005",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/glaxosmithkline-pharmaceuticals-793005"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "09-Jun-2026",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Letter For Website Link For Annual Report",
      "datetime": "08-Jun-2026",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "AGM Notice For 2025-26",
      "datetime": "05-Jun-2026",
      "details": "As per attachment",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>570%</strong> dividend, ex-date: 29 May 26",
          "dt": "2026-05-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18",
          "dt": "2018-09-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-05-12 10:10:46

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-04-20 10:10:48

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-04-09 10:10:32

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-04-06 08:01:52

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO, accompanied by a Mojo Score of 43.0, reflects growing concerns over its near-term price performance amid a challenging market environment.

Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-03-30 08:02:06

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum, underscoring challenges ahead for investors in this mid-cap pharmaceutical stock.

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-03-28 10:10:03

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

View All News